Brief: Galmed Signed Term Sheet For The Development Of Novel Semaglutide Sublingual Formulation
28/04/2025 13:02
April 28 (Reuters) - Galmed Pharmaceuticals Ltd GLMD.O: GALMED SIGNED TERM SHEET FOR THE DEVELOPMENT OF NOVEL SEMAGLUTIDE SUBLINGUAL FORMULATION GALMED PHARMACEUTICALS LTD - NEW FORMULATION OFFERS NON-INVASIVE ALTERNATIVE TO INJECTABLE SEMAGLUTIDE Source text: ID:nPn2hhnT5a Further company coverage: GLMD.O ((Reuters.Briefs@thomsonreuters.com;))